SCHEMBL3570241

SCHEMBL3570241

CCOC(=O)c1ccc(OC[C@@H]2CCCN2OCC(=O)OC(C)(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CHRNB2 P17787 4/20 0.43
CHRNA7 P36544 4/20 0.43
CHRNA4 P43681 4/20 0.43
CHRNA5 P30532 3/20 0.43
MAPT P10636 2/20 0.43
ADRB2 P07550 1/20 0.43
KCNH2 Q12809 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2434344 0.90 KDM4E (0.43) GAAMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL2432680 0.90 KDM4E (0.43) GAAMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL4808129 0.84 CHRNB2 (0.57) GAAL3MBTL1CHRNB2CHRNA7CHRNA4
SCHEMBL28524412 0.82 MEN1 (0.49) MEN1KMT2ACHRNB2CHRNA7CHRNA4
SCHEMBL2429206 0.82 MEN1 (0.49) MEN1KMT2ACHRNB2CHRNA7CHRNA4
SCHEMBL30213329 0.77 GPR119 (0.45) GAAMEN1KMT2AMAPTKCNH2
SCHEMBL21522595 0.76 CHRNB2 (0.53) L3MBTL1CHRNB2CHRNA7CHRNA4CHRNA5
SCHEMBL2433695 0.75 CHRNB2 (0.56) MEN1KMT2ACHRNB2CHRNA7CHRNA4
SCHEMBL7366249 0.75 CHEK2 (0.58) MAPTHPGDNPSR1
SCHEMBL3578221 0.73 ALDH1A1 (0.41) MEN1KMT2AMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100076202-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US disclosed
US-20070149607-A1 Method for producing pyrrolidine derivative DAICHI PAHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
EP-1698621-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076202-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE ALDH18A1, PLAAT4, ACSL4 GAA 588/4885MEN1 3920/4885KMT2A 647/4885
US-20070149607-A1 Method for producing pyrrolidine derivative ALDH18A1, PLAAT4, ACSL4 GAA 588/4885MEN1 3920/4885KMT2A 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.